Detalhe da pesquisa
1.
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Breast Cancer Res Treat
; 201(2): 215-225, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355526
2.
Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase III Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08).
Ann Surg
; 275(6): 1130-1136, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33055589
3.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863451
4.
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 122(7): 1119, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31949268
5.
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
BMC Cancer
; 20(1): 114, 2020 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32046665
6.
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
BMC Cancer
; 20(1): 166, 2020 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32111181
7.
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 120(10): 959-967, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30967649
8.
Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer.
Ann Surg
; 269(1): 83-87, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28742685
9.
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
BMC Cancer
; 19(1): 902, 2019 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31500588
10.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(1): 127-138, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158011
11.
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat
; 170(2): 351-360, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29589138
12.
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial.
Ann Surg Oncol
; 25(9): 2632-2640, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29948418
13.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 371(2): 107-18, 2014 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881463
14.
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
BMC Cancer
; 17(1): 265, 2017 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28407750
15.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Breast Cancer Res Treat
; 158(2): 323-31, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27372069
16.
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
BMC Cancer
; 16(1): 780, 2016 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27724870
17.
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Lancet Oncol
; 16(7): 848-58, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26092816
18.
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors.
BMC Cancer
; 13: 153, 2013 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23530694
19.
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
J Geriatr Oncol
; 14(1): 101372, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36127284
20.
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
J Clin Oncol
; 41(7): 1376-1382, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36521078